J. Kaern

发表

Prognostic value of pre‐ and postoperative serum CA 125 levels in ovarian cancer: New aspects and multivariate analysis

V. Abeler, C. Tropé, G. Kristensen, 1992, Gynecologic oncology.

Borderline ovarian tumours.

B. Davidson, C. Tropé, J. Kaern, 2012, Best practice & research. Clinical obstetrics & gynaecology.

Genetic alterations of the TP53 gene, p53 protein expression and hpv infection in primary cervical carcinomas

J. Nesland, A. Børresen, R. Holm, 1993, The Journal of pathology.

DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary

V. Abeler, E. Pettersen, C. Tropé, 1993, International Journal of Gynecologic Cancer.

Flow cytometric DNA measurements in squamous cell carcinoma of the vulva: an important prognostic method

E. Pettersen, C. Tropé, J. Kaern, 1991, International Journal of Gynecologic Cancer.

Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse.

V. Abeler, I. Vergote, E. Pettersen, 1993, American journal of obstetrics and gynecology.

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients

V. Gebski, I. Vergote, C. Marth, 2012, British Journal of Cancer.

No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers.

K. Byth, J. Nesland, M. Friedlander, 2004, Gynecologic oncology.

Tamoxifen in the treatment of recurrent ovarian carcinoma.

C. Tropé, C. Marth, J. Kaern, 2000, European journal of cancer.

Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients.

C. Tropé, G. Kristensen, C. Marth, 2000, Gynecologic oncology.

First‐line treatment of ovarian cancer FIGO stages IIb–IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin

E. Eisenhauer, I. Vergote, G. Kristensen, 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

First-line treatment of ovarian cancer FIGO stages IIb–IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin

E. Eisenhauer, I. Vergote, G. Kristensen, 2003, International Journal of Gynecologic Cancer.

Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

M. Piccart, K. Swenerton, I. Vergote, 2003, International Journal of Gynecologic Cancer.

Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells.

O. Dapunt, M. Widschwendter, C. Tropé, 1997, Cancer research.

Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum‐sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry‐based study

C. Tropé, T. Myklebust, J. Kaern, 2018, Acta obstetricia et gynecologica Scandinavica.

Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer.

C. Tropé, K. Kjaerheim, T. Haldorsen, 2006, Gynecologic oncology.

A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG).

V. Gebski, I. Vergote, S. Pignata, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary.

V. Abeler, E. Pettersen, C. Tropé, 1990, Gynecologic oncology.

Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short‐ and long‐term survivors?

J. Nesland, M. Friedlander, H. Danielsen, 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients.

C. Tropé, J. Kaern, M. Baekelandt, 2002, European journal of gynaecological oncology.

Prognosis and management of borderline tumours of the ovary.

C. Tropé, J. Kaern, 1996, Current opinion in obstetrics & gynecology.

Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial.

V. Gebski, I. Vergote, S. Pignata, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term results from a phase II study of paclitaxel combined with doxorubicin in recurrent platinum refractory ovarian cancer.

C. Tropé, G. Kristensen, J. Kaern, 2001, European journal of gynaecological oncology.

Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors.

V. Abeler, I. Vergote, C. Tropé, 1993, Gynecologic oncology.

Human papilloma virus has no prognostic significance in cervical carcinoma.

V. Abeler, C. Tropé, G. Kristensen, 1996, European journal of cancer.

Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells.

M. Widschwendter, C. Marth, G. Daxenbichler, 1997, British Journal of Cancer.

Papillomaviruses, p53, and cervical cancer

A. Børresen, D. Levison, R. Holm, 1992, The Lancet.

Management of borderline tumors of the ovary: state of the art.

C. Tropé, J. Kaern, 1998, Seminars in oncology.

Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.

V. Gebski, G. Kristensen, P. Witteveen, 2017, Gynecologic oncology.

Impact of hospital type and treatment on long-term survival among patients with FIGO Stage IIIC epithelial ovarian cancer: follow-up through two recurrences and three treatment lines in search for predictors for survival.

I. Vistad, C. Tropé, J. Kaern, 2016, European journal of gynaecological oncology.

Gestational trophoblastic tumors in Norway, 1968-1997: patient characteristics, treatment, and prognosis.

T. Bjørge, V. Abeler, C. Tropé, 2002, Gynecologic oncology.

Evaluation of genomic changes in a large series of malignant ovarian germ cell tumors--relation to clinicopathologic variables.

J. Sudbø, R. Lothe, V. Abeler, 2004, Cancer genetics and cytogenetics.

Placental site trophoblastic tumor (PSTT) in mother and child: first report of PSTT in infancy.

V. Abeler, J. Kaern, T. Monclair, 2002, Medical and pediatric oncology.

Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature.

C. Tropé, J. Kaern, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status.

A. Børresen-Dale, B. Smith-Sørensen, R. Holm, 1998, British Journal of Cancer.

Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients.

S. Saebøe-Larssen, G. Kvalheim, J. Kaern, 2013, International journal of oncology.

Molecular and biological factors in the pathogenesis of ovarian cancer.

G. Rustin, J. Berek, C. Tropé, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma.

E. Pettersen, C. Tropé, G. Kristensen, 1995, Acta oncologica.

DNA copy number changes in malignant ovarian germ cell tumors.

R. Lothe, V. Abeler, P. Peltomäki, 2000, Cancer research.

Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument

V. Abeler, E. Pettersen, C. Tropé, 2000, International Journal of Gynecologic Cancer.

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

M. Piccart, K. Swenerton, B. Zee, 2000, Journal of the National Cancer Institute.

Malignant melanoma of the vulva FIGO stage I: Evaluation of prognostic factors in 43 patients with emphasis on DNA ploidy and surgical treatment.

V. Abeler, E. Pettersen, C. Tropé, 1996, Gynecologic oncology.

Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer.

I Vergote, H E Danielsen, V. Abeler, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary adenocarcinoma localized to the fallopian tubes: report on 33 cases.

V. Abeler, J. Kaern, M. Asmussen, 1988, Gynecologic oncology.

Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer.

B. Davidson, F. Saatcioglu, C. Tropé, 2004, Gynecologic oncology.

The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma.

V. Abeler, V. A. Flørenes, B. Davidson, 2006, Gynecologic oncology.

Comparison between flow cytometry and image cytometry in ploidy distribution assessments in gynecologic cancer.

A. Reith, H. Danielsen, E. Pettersen, 1992, Cytometry.

Influence of HSP27 and steroid receptor status on provera sensitivity, DNA-ploidy and survival of females with endometrial cancer

D. Sumner, C. Tropé, J. Kaern, 1994, International Journal of Gynecologic Cancer.

A phase II study of 5-fluorouracil/cisplatinum in recurrent cervical cancer.

V. Abeler, C. Tropé, J. Kaern, 1990, Acta oncologica.

Bleomycin‐ifosfamide‐cis‐platinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: A second look

J. Kaern, K. Ramm, I. Vergote, 1993, Gynecologic oncology.

Intrauterine Growth in Twin Pregnancies: Prediction of Fetal Growth Retardation

J. Kaern, P. K. Hansen, N. Secher, 1985, Obstetrics and gynecology.

Diagnosis and treatment of borderline ovarian neoplasms "the state of the art".

V. Abeler, B. Davidson, C. Tropé, 2009, European journal of gynaecological oncology.

Cancer of the endometrium: value of MR imaging in determining depth of invasion into the myometrium.

V. Abeler, C. Tropé, J. Kaern, 1991, AJR. American journal of roentgenology.

The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma.

E. Pettersen, C. Tropé, G. Kristensen, 1996, Gynecologic oncology.

HLA antigens and cervical carcinoma

E. Thorsby, Å. Helland, J. Kaern, 1992, Nature.

Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?

M. Friedlander, H. Danielsen, C. Tropé, 2004, International Journal of Gynecologic Cancer.

Adjuvant Treatment for Early-Stage Epithelial Ovarian Cancer

C. Tropé, J. Kaern, 2004 .

Chromosome 2q24.2 is lost in sporadic but not in BRCA1‐associated ovarian carcinomas

J. Nesland, M. Friedlander, K. Tucker, 2006, Pathology.

Primary surgery for ovarian cancer.

C. Tropé, J. Kaern, J. Kærn, 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

DNA ploidy and expression of p53 and C-erbB-2 in extramammary Paget's disease of the vulva.

E. Pettersen, C. Tropé, J. Kaern, 1997, Gynecologic oncology.

V. Gebski, I. Vergote, S. Pignata, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel in untreated FIGO stage III suboptimally resected ovarian cancer.

C. Tropé, G. Kristensen, J. Kaern, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

A PHASE II STUDY OF 5-FU/ CIS IN RECURRENT CERVICAL CANCER

V. Abeler, C. Tropé, J. Kaern, 1990 .

Evaluation of deoxyribonucleic acid ploidy and S‐phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma: A prospective study

E. Pettersen, G. Kristensen, K. Tveit, 1994, American journal of obstetrics and gynecology.

Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience.

A. Jacobsen, U. Puistola, C. Tropé, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Human germ cell tumours: expression of γ-glutamyl transpeptidase and sensitivity to cisplatin

H. Frierson, V. Abeler, J. Kaern, 1999, British Journal of Cancer.

[Examination, treatment and follow-up of ovarian cancer in Norway].

K. Kjaerheim, J. Kaern, T. Paulsen, 2001, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

Colony-forming ability of human ovarian carcinomas in the Courtenay soft agar assay.

V. Abeler, E. Pettersen, C. Tropé, 1989, Anticancer research.

Long‐term follow‐up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

M. Piccart, K. Swenerton, I. Vergote, 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Improved short‐term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals

S. Tretli, C. Tropé, J. Kaern, 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Randomized trial on adjuvant carboplatin versus no treatment in stage I high risk ovarian cancer by th Nordic Ovarian Cancer Study Group (NOCOVA)

I. Vergote, C. Tropé, T. Högberg, 1997 .

Long-term follow-up of neoadjuvant cisplatin and 5-fluorouracil chemotherapy in bulky squamous cell carcinoma of the cervix.

C. Tropé, C. Marth, K. Sundfør, 1999, Acta oncologica.

Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up.

C. Tropé, G. Kristensen, J. Kaern, 1996, Gynecologic oncology.